JUXTAPID

This brand name is authorized in United States. It is also authorized in Canada, Japan.

Active ingredients

The drug JUXTAPID contains one active pharmaceutical ingredient (API):

1	Lomitapide UNII X4S83CP54E - LOMITAPIDE MESYLATE
	Lomitapide is a selective inhibitor of microsomal transfer protein (MTP), an intracellular lipid-transfer protein that is found in the lumen of the endoplasmic reticulum and is responsible for binding and shuttling individual lipid molecules between membranes. MTP plays a key role in the assembly of apo B containing lipoproteins in the liver and intestines. Inhibition of MTP reduces lipoprotein secretion and circulating concentrations of lipoprotein-borne lipids including cholesterol and triglycerides.
	Read more about Lomitapide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JUXTAPID Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AX12		C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AX Other lipid modifying agents
Discover more medicines within C10AX12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02420341, 02420376, 02420384
JP	医薬品医療機器総合機構	2189020M1023, 2189020M2020, 2189020M3026
US	FDA, National Drug Code	76431-105, 76431-110, 76431-120, 76431-130